Coagulation and Fibrinolysis of Estradiol in Transwomen
Status:
Recruiting
Trial end date:
2022-12-07
Target enrollment:
Participant gender:
Summary
The specific aim for our study is to measure coagulation system activation and fibrinolysis
following transdermal versus sublingual versus oral estradiol versus in transgender women.
Hypothesis: Transdermal estradiol will result in less coagulation system activation and no
effect on plasminogen activator inhibitor (PAI-1) or tissue-type plasminogen activator
(t-PA). Oral estradiol will result in the most coagulation system activation and effect on
PAI-1 and t-PA: Oral estradiol > sublingual estradiol > transdermal estradiol.
A prospective crossover study will include ten subjects given estradiol 1 mg daily and
instructed to take it orally, sublingually, or transdermal for 2 months with a 2-week washout
period between routes of administration. Labs will be measured 7 times during the study.